| Project/Area Number |
60480176
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Immunology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
FUJIWARA Hiromi Osaka Univ. Med. Sch., Inst. for Cancer Res., 医学部, 助教授 (70116094)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HAMAOKA Toshiyuki Osaka Univ. Med. Sch., Inst. for Cancer Res., 医学部, 教授 (60028529)
|
|---|
| Project Period (FY) |
1985 – 1986
|
| Project Status |
Completed (Fiscal Year 1986)
|
| Budget Amount *help |
¥6,800,000 (Direct Cost: ¥6,800,000)
Fiscal Year 1986: ¥2,800,000 (Direct Cost: ¥2,800,000)
Fiscal Year 1985: ¥4,000,000 (Direct Cost: ¥4,000,000)
|
|---|
| Keywords | Lyt- <1^+> <2^-> T cells / helper T cells / delayed-type hypersensitivity / antigen-presenting cells / major histocompatibility complex antigens / 免疫寛容 |
|---|
| Research Abstract |
This purpose aimed to (1) establish various assay systems capable assessing activities of Lyt- <1^+> <2^-> T cells responsible for various immune responses in vivo and (2) to analyze the mechanisms by which these T cells recognize antigens and (3) to investigate the manipulation of in vivo immune phenomena such as tumor or allograft rejections and autoimmune disease by regulating the induction of the Lyt- <1^+> <2^-> T cells
The results demonstrated that (1) assay systems were established for assessing various Lyt- <1^+> <2^-> T cell activities. These included helper T cell activities assisting CTL or antibody responses to cell-bound antigens (cell surface antigens), and delayed-type hypersensitivity responses; (2) lyt- <1^+> <2^-> T cells can recognize cell surface antigens when these antigens are shed off from cell surfaces, processed by antigen-presenting cells (APC) and presented by APC in association with class II MHC antigens on APC; and (3) portal venous administration of allogeneic cells results in alloantigen-specific tolerance of delayed-type hypersensitivity responses and this approach is applicable to the regulation of transplantation immunity particularly when combined with an appropriate drug such as cyclophos-phamide.
|
